Home > Healthcare > Medical Devices > Diagnostic Devices > Liver Disease Diagnostics Market

Liver Disease Diagnostics Market Trends

Report ID: GMI7939
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Liver Disease Diagnostics Market Trends

Numerous factors are influencing the dynamics and expansion of the industry. These trends reflect the surging demand for integration of artificial intelligence (AI) in healthcare and machine learning in liver disease, rising focus on viral hepatitis testing, and growing need for point-of-care testing, among other factors.

Non-invasive methods of diagnosis are growing increasingly popular for liver illnesses. Elastography, transient elastography (FibroScan), magnetic resonance elastography (MRE), and shear wave elastography are all techniques used to precisely determine liver fibrosis without requiring invasive procedures like liver biopsy.
Moreover, early detection and preventive measures are highly prioritized in the treatment of liver related diseases. Early detection enables quick treatment and reduction of disease growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for liver disease diagnostics was valued at around USD 39.5 billion in 2023 and is estimated to reach over USD 74.6 billion by 2032 owing to the increasing prevalence of liver diseases, growing awareness regarding liver related complications and the importance of early diagnosis.

The laboratory tests segment of market accounted for over 38.1% share in 2023 and is anticipated to witness notable growth through 2032 as these tests are commonly prescribed in various clinical settings to screen for liver diseases.

North America market accounted for USD 16.2 billion in 2023 and is estimated to witness substantial market growth over 2024 and 2032 due to the obesity pandemic prevalent in the region.

Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd., F. Hoffmann-La Roche Ltd., HORIBA Medical, Laboratory Corporation of America Holdings, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.